Jason S. Ehrlich

Ophthalmology

2680 Hanover St
Palo Alto, CA 94304

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Report of the 2023 Mary Tyler Moore Vision Initiative Workshop.

Report of the 2023 Mary Tyler Moore Vision Initiative Workshop.

Journal: Translational vision science & technology

Published: July 18, 2025

Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial.

Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial.

Journal: JAMA ophthalmology

Published: July 31, 2020

Ranibizumab in Diabetic Retinopathy with or without Diabetic Macular Edema.

Ranibizumab in Diabetic Retinopathy with or without Diabetic Macular Edema.

Journal: Ophthalmology. Retina

Published: April 21, 2020

Diabetic Population-Based Model to Estimate Impact of Ranibizumab on Diabetic Retinopathy Severity in Patients with Diabetic Macular Edema.

Diabetic Population-Based Model to Estimate Impact of Ranibizumab on Diabetic Retinopathy Severity in Patients with Diabetic Macular Edema.

Journal: Clinical ophthalmology (Auckland, N.Z.)

Published: November 01, 2019

The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial.

The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial.

Journal: Ophthalmology

Published: December 19, 2018

Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials.

Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials.

Journal: JAMA ophthalmology

Published: May 26, 2018

The Clinical Importance of Changes in Diabetic Retinopathy Severity Score.

The Clinical Importance of Changes in Diabetic Retinopathy Severity Score.

Journal: Ophthalmology

Published: September 16, 2016

Effect of Ranibizumab on the Decision to Drive and Vision Function Relevant to Driving in Patients With Diabetic Macular Edema: Report From RESTORE, RIDE, and RISE Trials.

Effect of Ranibizumab on the Decision to Drive and Vision Function Relevant to Driving in Patients With Diabetic Macular Edema: Report From RESTORE, RIDE, and RISE Trials.

Journal: JAMA ophthalmology

Published: November 20, 2015

Targeting the Effect of VEGF in Diabetic Macular Edema.

Targeting the Effect of VEGF in Diabetic Macular Edema.

Journal: The New England journal of medicine

Published: July 30, 2015

Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy: Long-Term Outcomes of the Phase III RIDE and RISE Trials.

Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy: Long-Term Outcomes of the Phase III RIDE and RISE Trials.

Journal: Ophthalmology

Published: March 06, 2015

Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials.

Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials.

Journal: Ophthalmology

Published: April 07, 2014

Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.

Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.

Journal: Ophthalmology

Published: March 27, 2014

Showing 1-12 of 20

Last Updated: 09/26/2026